HCW Biologics Inc. announced positive preliminary human data readouts from the first two dose cohorts of its dose-escalating Phase 1 clinical trial evaluating HCW9302 monotherapy in patients with alopecia areata. The data indicated that all participants in the second dose cohort showed a positive clinical response after a single dose administration, with no dose-limiting toxicities or significant adverse effects reported. The company is progressing through dose escalation in this clinical study, aiming to establish the recommended Phase 2 dose by the end of 2026.

In the second dose cohort, all three participants who received a single subcutaneous dose of three micrograms/kg body weight showed preliminary indications of improvement in Severity of Alopecia Tool (SALT) scores. These participants, all with mild alopecia, demonstrated a ≥25% reduction in SALT scores compared to baseline at four and/or nine weeks after dosing. Treatment of patients in the third dose cohort, set at eight micrograms/kg body weight, is currently underway.

The safety profile of HCW9302 was well tolerated across the first and second dose cohorts, which received one microgram/kg and three micrograms/kg respectively. There were no reported incidences of capillary leak or cytokine release syndromes associated with high dose intravenous IL-2 therapy. Additionally, the treatment did not increase blood eosinophil counts. All reported treatment emergent adverse events were mild, self-limiting, and resolved without medical intervention, with the most common side effect being a temporary injection-site reaction.

Mechanism of Action and Future Plans

Dr. Hing C. Wong, the Company's Founder and Chief Executive Officer, stated that the results are consistent with pre-clinical studies demonstrating HCW9302 exhibits a strong IL-2 receptor α bias. This mechanism preferentially expands and stimulates regulatory T cells to reduce pro-inflammatory and autoimmune responses. HCW9302 is comprised of all human-derived components and can be produced with a cost-effective, streamlined process similar to therapeutic monoclonal antibodies.

HCW Biologics projects to establish the recommended Phase 2 dose by year-end 2026. Patient enrollment remains on track, and the company has initiated dosing patients in the third dose escalation cohort. Upon establishing the recommended Phase 2 dose, the company plans to consider expanding clinical studies to evaluate multi-dose HCW9302 monotherapy in patients with alopecia areata, as well as other conditions such as vitiligo, atopic dermatitis, and Amyotrophic Lateral Sclerosis.

Trial Details

The Phase 1 multi-center dose-escalation study (Clinicaltrials.gov: NCT07049328) is designed to treat up to 30 patients with alopecia areata. The primary objectives are to evaluate the safety of HCW9302 and determine the recommended dose level for later phase clinical studies. Secondary objectives include assessing disease responses and the effects on immune cell proliferation and function. Active clinical sites enrolling patients include The Ohio State University Wexner Medical Center and the James A. Haley Veterans' Hospital.

HCW Biologics has filed a prospectus for an offering of 5.69 million common shares. The filing was submitted to the SEC.

Filing Details

The prospectus was filed with the U.S. Securities and Exchange Commission (SEC). The document outlines the company's intention to offer the shares to the public.

Offering Overview

The filing provides regulatory details regarding the proposed share offering. Further information regarding pricing and timing is expected to be disclosed in subsequent filings.